Pharmacological treatment of early multiple sclerosis

Olaf Stuve, Jeffrey L. Bennett, Bernhard Hemmer, Heinz Wiendl, Michael K. Racke, Amit Bar-Or, Wei Hu, Robert Zivadinov, Martin S. Weber, Scott S. Zamvil, Maria Fides Manago Pacheco, Til Menge, Hans Peter Hartung, Bernd C. Kieseier, Elliot Frohman

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


Currently, six medications are approved by the US FDA for the treatment of relapsing forms of multiple sclerosis (MS). In contrast, no pharmacological agent has proved to be effective in patients with secondary-progressive MS without relapses, or in patients with primary-progressive MS. One of the principal issues concerning an optimal pharmacotherapy for relapsing forms of MS is the optimal time of treatment initiation. There is now an almost universal consensus among MS experts that many patients will benefit from early therapy. However, several formidable challenges exist in identifying individuals who will benefit versus those who will do well without intervention. How do we define early MS and what clinical and paraclinical markers may be useful in defining the timing and nature of therapy? Do patients with a benign form of MS require therapy or are they exposed unnecessarily to adverse effects of our currently available medications? How do we identify disease progression and treatment failures? This review discusses these issues and outlines the evidence for application of 'early' treatment in patients with relapsing forms of MS.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
Issue number1
StatePublished - 2008


  • Interferon beta 1a, therapeutic use
  • Interferon beta 1b, therapeutic use
  • Multiple sclerosis, treatment

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Pharmacological treatment of early multiple sclerosis'. Together they form a unique fingerprint.

Cite this